Safety of oral terbinafine: Results of a postmarketing surveillance study in 25 884 patients

Archives of Dermatology

Volumn 133, Issue 10, 1997, Pages 1213-1219

  Hall, Michael ^a,b,d   Monka, Carmen ^b,d   Krupp, Pierre ^b,d   O'Sullivan, Desmond ^c,d  

^a Sandoz Pharma Ltd   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Novartis Pharmaceuticals Uk Limited   (United Kingdom)

^d Novartis Pharma AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ASTEMIZOLE; CIMETIDINE; ORAL ANTIDIABETIC AGENT; STEROID; TERBINAFINE; TERFENADINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BRONCHOSPASM; CHILD; CLINICAL TRIAL; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATOBILIARY DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; ONYCHOMYCOSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PRURITUS; RASH; SKIN DISEASE; THROMBOCYTOPENIA; TOPICAL DRUG ADMINISTRATION;

EID: 0030824856     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.133.10.1213     Document Type: Article

References (12)

1. Roberts DT. Oral therapeutic agents in fungal nail disease. J Am Acad Dermatol. 1994;31(suppl):S78-S81.
2. Roberts DT. Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey. Br J Dermatol. 1992;126(suppl 39):23-27.
3. Lubeck DP, Patrick DL, McNulty P, Fifer SK, Birmbaum J. Quality of life of persons with onychomycosis. Qual Life Res. 1993;2:341-348.
4. Kemna ME, Elewski BE. A US epidemiologic survey of superficial fungal diseases. J Am Acad Dermatol. 1996;35:539-542.
5. Summerbell RC, Kane J, Krajden S. Onychomycosis, tinea pedis, and tinea manuum caused by non-dermatophytic filamentous fungi. Mycoses. 1989;32:609-619.
6. Hay RJ. Onychomycosis: agents of choice. Dermatol Ther. 1993;11:161-169.
7. Hay RJ, Clayton YM, Moore MK, Midgeley G. An evaluation of itraconazole in the management of onychomycosis. Br J Dermatol. 1988;119:359-366.
8. Elewski B. Mechanisms of action of systemic antifungal agents. J Am Acad Dermatol. 1993;28(suppl):S28-S34.
9. Lamisil® (terbinafine hydrochloride tablets). Physicians' Desk Reference. 51st ed. Montvale, NJ: Medical Economics; 1997:2394-2395.
10. O'Sullivan DP, Meedham CA, Bangs A, Atkin K, Kendall FD. Postmarketing surveillance of oral terbinafine in the UK. Br J Clin Pharmacol. 1996;42:559-565.
11. Back DK, Stevenson P, Tjia JF. Comparative effects of two antimycotic agents, ketoconazole and terbinafine, on the metabolism of tolbutamide, ethinyloestradiol, cyclosporin and ethoxycoumarin by human liver microsomes in vitro. Br J Clin Pharmacol. 1989;28:166-170.
12. Villars W, Jones TC. Special features of the clinical use of oral terbinafine in the treatment of fungal diseases. Br J Dermatol. 1992;126(suppl 39):61-69.